IGC IGC Pharma, Inc.

Overview and Growth

In fiscal 2025, IGC Pharma, Inc. recorded $1.27M of revenue, net loss of $7.12M, and an operating cash outflow of $4.79M. Revenue of $1.27M sets the scale for evaluating how effectively sales translated into profit and cash during the year. The top line contracted 5.5% from $1.34M in fiscal 2024; this top-line contraction left the company with a smaller revenue base. The company reported diluted EPS of -$0.09, adding a shareholder-level measure to the absolute income figures considered below. The company employed $8.75M of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 0.15x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

After reported cost of revenue, the company retained $619.00K as gross profit before recognizing operating expenses and other items. Gross margin was 48.7%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was an operating loss of $7.45M, reflecting costs that exceeded gross profit. Relative to revenue, the operating deficit measured 585.8%, showing the shortfall after operating costs. The bottom-line result was a net loss of $7.12M after operating, financing, tax, and other recognized items. Net margin was -560.3%, reflecting a loss equal to 560.3% of reported revenue. The pretax result was a loss of $7.12M, establishing the deficit before tax effects. The pretax loss equaled 560.3% of revenue, measuring the pre-tax deficit against sales. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 112.5%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 81.4%, placing the bottom-line deficit against the company’s resource base.

Liquidity and Capital Structure

Total assets were $8.75M, supported by $2.42M of liabilities and $6.33M of shareholder equity. The near-term balance sheet paired $2.90M of current assets with $2.26M of current liabilities at the reporting date. At 1.28x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $405.00K in cash and equivalents, a narrower liquidity measure than total current assets. Measured only with cash and equivalents, coverage of current liabilities was 17.9%, excluding receivables and other current assets. Borrowings totaled $137.00K, adding a fixed financing obligation alongside the company’s equity capital. The debt-to-equity relationship was 0.02x, showing how much debt the company carried for each unit of book equity. The debt-to-assets relationship was 1.6%, comparing borrowing with the total asset balance. Relative to total assets, liabilities measured 27.6%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 4.6% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 11.7% from $9.90M in fiscal 2024, leaving current total assets lower year over year. Against $7.32M of equity in fiscal 2024, the current book-equity balance moved 13.5% and ended lower. Compared with $1.20M in fiscal 2024, the current cash balance moved 66.2% and finished lower.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $4.79M, showing that operations absorbed cash during the period. Capital expenditures used $112.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. The company recorded a $4.91M cash deficit after capital spending for the period. The free-cash-flow deficit equaled 386.1% of revenue, showing the post-investment cash shortfall relative to sales. The free-cash-flow deficit equaled 56.1% of total assets, placing the cash shortfall against the company’s resource base.

Based on the annual report for the fiscal year ending Mar 31, 2025. Analysis generated Oct 21, 2026.